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Background:  Cardioprotective (CP) medications decrease the risk of developing chemotherapy-induced cardiotoxicity (CTX), but have 
associated side effects and additional cost. We sought the most cost-effective strategy for CP.
methods:  A Markov model was used to compare survival, quality-adjusted life-years (QALYs) and costs (calculated from a US healthcare 
perspective) for 3 strategies: LVEF-guided therapy (EFGT), uniform CP (UCP) or 2D strain echo guided therapy (SGT) over a 5 year 
horizon. We utilized our observations and the available literature to quantify associated risks, transition probabilities and costs. Sensitivity 
analyses were performed on all variables.
results:  The 5-year cumulative costs and QALYs per patient for SGT, UCP and EFGT are listed in Table 1. Strain-guided CP showed 
incremental benefit over UCP, with incremental CE-ratio (ICER) of $4,138±$12,121 per QALY gained, and dominance over EFGT, with 
cost savings of $1236 and QALY savings of 0.23. Model results were stable over a wide range of all variables, but variations in the cost 
of cardioprotective medications and probabilities of cardioprotection side-effects had modest effect, with strain-guided cardioprotection 
dominating UCP at or above annual medication costs >$735 and side-effect costs >$1840.
conclusion:  2D-strain guided therapy in patients at risk of CTX provides more QALYs at lower cost than usual (EF-guided) therapy.
Cost and Utility Outcomes of Cardioprotective Strategies over 5 Years
Strategy Cumulative Cost (US$) Cumulative Effectiveness (QALYs) ICER (US$/QALY) Five-year survival
Uniform therapy $13, 987 ±$15,522 3.70±0.80 - 79%
Strain-guided therapy $14,318 ±$18,701 3.78±0.77 $4137 82%
LVEF-guided therapy $15,554 +$17,020 3.55±0.82 Dominated 76%
